Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00705094
First received: June 23, 2008
Last updated: September 29, 2014
Last verified: September 2014

June 23, 2008
September 29, 2014
September 2008
May 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00705094 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.

The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

testicular cancer patients who have recieved surgery and are scheduled for either chemotherapy or surveillance

  • Testicular Cancer
  • Seminoma
  • Non-seminomatous
Not Provided
  • 1
    Testicular cancer patients who have received surgery and are scheduled for surveillance
  • 2
    Testicular cancer patients who have received surgery and are scheduled for chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
July 2012
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • surgery and surveillance
  • surgery and multi-cycle chemotherapy
  • both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors
  • Karnofsky performance index > 70%
  • no contraindications to cardiopulmonary testing

Exclusion Criteria:

  • documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00705094
GU-24167
No
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Mark Haykowsky, PhD University of Alberta
AHS Cancer Control Alberta
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP